Clinical trial
SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
NCT03574597 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 24, 2018
- Completion date
- June 29, 2023
- Enrollment
- 17,604 (actual)
- Sites
- 833
Conditions
As the registry lists them; a condition with its own page is linked.